---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-25-000044"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:09:52.996774+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma posts record Q1 revenue $197.1M (+43%); raises FY2025 guidance

## Summary
- Record Q1 net revenue $197.1M (+43.4% YoY); Rare Disease $69.0M (Cortrophin Gel $52.9M, +43.1%).
- Record adjusted non-GAAP EBITDA $50.7M (+34.9%); adjusted diluted EPS $1.70, up from $1.21 YoY.
- Generics revenue $98.7M (+40.5%) driven by new launches including first-to-market prucalopride.
- Raised 2025 guidance: net revenue $768M-$793M, EBITDA $195M-$205M, adjusted EPS $6.27-$6.62.

## SEC filing metadata
- accession: 0001023024-25-000044
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000044/0001023024-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000044/ani-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-25-000044
- JSON: https://secwatch.observer/filing/0001023024-25-000044.json
- Plain text: https://secwatch.observer/filing/0001023024-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.